Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Rx Trends Showing Impact Of Fewer Drug Approvals, IMS Data Suggest

Executive Summary

New prescription growth rates in the U.S. appear to reflect a drop-off in the number of new drugs clearing FDA, IMS VP-Industry Relations Doug Long told the Pharmaceutical Care Management Association annual meeting Oct. 14 in Henderson, Nev.
Advertisement

Related Content

CVS Says Lack Of New Drug Launches Is One Reason For Earnings Decline
Rx Discounts Are “Price Industry Must Pay” For Medicare Benefit – Novartis
Roche Accutane Prescriber Registry Added To Pregnancy Prevention Program
CVS Says Lack Of New Drug Launches Is One Reason For Earnings Decline
Roche Accutane Prescriber Registry Added To Pregnancy Prevention Program
Rx Discounts Are “Price Industry Must Pay” For Medicare Benefit – Novartis
Advertisement
UsernamePublicRestriction

Register

PS038722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel